Bioaffinity Technologies, Inc. · NASDAQ:BIAF
Bioaffinity Technologies — H.C. Wainwright Annual Global Investment Conference 2025
18 slides from Bioaffinity Technologies's conference presentation, Sep 5, 2025
Slide 1: Company Presentation: CyPath Lung Noninvasive, Accurate Lung Cancer Detection
bioAffinit TECHNOLOGIES NASDAQ: BIAF / BIAFW May not be without y Company Presentation H.C. Wainwright 27"? Annual Global Investment Conference CyPath Lung Noninvasive, Accurate Lung Cancer Detection Copyright © 2025 bioaffinity Technologies, Inc. BA-25003 4/25
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation and statements by management or other persons acting by or on behalf of bioAffinity Technologies made in connection with this presentation constitute “forward-looking statements” within the meaning of the sa
Slide 3: Lung Cancer Is A Global Problem and Large Market
Lung Cancer Is A Global Problem and Large Market Most common cancer and leading cause of cancer-related deaths * 248 million new cases of lung cancer worldwide in 2022, with 1.8 million deaths annually! o An estimated 19.3 million Americans should have annual lung cancer screening, according to the
Slide 4: bioAffinity Technologies' Diagnostic Platform Starts with CyPath Lung
bioAffinity Technologies’ Diagnostic Platform Starts with CyPath Lung We Tackled the Most Difficult Problem First: Lung Cancer SW Growing Platform Technology Oye Gj 2\ + Our commercial noninvasive lung cancer test is the first in a pipeline that includes development of companion diagnostics for asth
Slide 5: Urgent Need for Early Detection of Lung Cancer
Urgent Need for Early Detection of Lung Cancer Only 28% of patients with lung cance vive 5 years! * 63% of patients with Stages Ill lung cancer survive 5 years! * Most patients are diagnosed with late-stage (Stages III- \V) lung cancer when survival is much lower! 92% of Stage | patients survive 10
Slide 6: Patient Case Studies Reveal CyPath Lung Finds Cancer at Curative Stage 1A
Patient Case Studies Reveal CyPath® Lung Finds Cancer at Curative Stage 1A — Detected Stage 1A adenocarcinoma in 67-year-old woman when risk models suggested a low probability of cancer and other diagnostics were contraindicated. CyPath® Lung led to biopsy and curative treatment. Stage 1A mucinous a
Slide 7: Savings to Individual and Overall Healthcare With CyPath Lung
Savings to Individual and Overall Healthcare With CyPath Lung 2024 study! authored by pulmonologists practicing at Audie L. Murphy Memorial VA Hospital and Brooke Army Medical Center evaluated CyPath’ Lung’s economic impact if added to the standard of care in 2022 Conclusion: Significant savings to
Slide 8: Physician-Focused, Patient-Friendly CyPath Lung
Physician-Focused, Patient-Friendly CyPath Lung More Accurate Diagnosis With Fewer Unnecessary Invasive Procedures "a — > oo ) ships | q overnight ry Physician orders CyPath’ Lung test to ship to patient or deliver in clinic Patient videos, instructions, personal coach assist with 3-day collection a
Slide 9: Established CAP/CLIA Laboratory - Precision Pathology Laboratory Services
Established CAP/CLIA Laboratory - Precision Pathology Laboratory Services Precision Pathology Laboratory Services — a wholly owned subsidiary of bioAffinity Technologies — offers CyPath Lung as a Laboratory Developed Test b Offi n ity TECHNOLOGIES * Current capacity for nationwide expansion of CyPat
Slide 10: How the CyPath Lung Test Works
How the CyPath Lung Test Works Flow cytometry interrogates sputum cells after sample processing S y * Test uses antibodies, reagents, labeling agents and TCPP, a synthetic porphyrin that labels cancer and cancer-related cells * Sputum samples are processed into a single-cell suspension and labelled
Slide 11: CyPath Lung Comparison vs Standard-of-Care Follow-Up
CyPath Lung Comparison vs Standard-of-Care Follow-Up Lung Cancer Diagnostic Procedure or Test Sensitivity Specificity finaniduals : high risk with nodules <20mm) a 87% (individuale ah susplotous lung nodules) 89% 75% (ediiduale ath suspicious lung nodules) a 47% fnghiauals witha reploiois lung nodul
Slide 12: Milestones Accomplished in 2024
Milestones Accomplished in 2024 2024 sales nearly 14x higher vs prior years Sales team expands to cover all major Texas Medicare reimbursement code effective for Awarded right to sell to VA/government Completed beta Medicare & private market launch for insurers begin reimbursing test CyPath® Lung in
Slide 13: Major Milestones to Achieve in 2025
Forecasting increased sales Major Milestones to Achieve in 2025 media promotion programs D> 3X vs 2024 ‘= a) x te} . , 2 Begin continuous Increase market Enter major VA Enter strategic Expand sales team as reporting of case awareness medical centers with regional markets in and marketing into ® stud
Slide 14: Our Pipeline: Companion Diagnostics for $26 Billion Market
Our Pipeline: Companion Diagnostics for $26 Billion Market Asthma and COPD treatments work, but not for everyone. Our noninvasive tests aim to ensure patients receive the right treatment for their disease Our pipeline of companion diagnostics targets a large global markets estimated at $26 billion f
Slide 15: Management - Innovative, Experienced, Dedicated
Management-— Innovative, Experienced, Dedicated Xavier Reveles, MS, Maria Zannes, JD Michael Edwards, Gordon Downie, MD, PhD William Bauta, PhD icG(ascp)c™ Founder, CEO & MBA, CPA \? Chief Medical Officer Chief Science Officer Chief Operating Officer President CFO. 30+ years C-suite executive 30+ ye
Slide 16: Board of Directors
Board of Directors Decades of Successful Leadership from Start-Ups to Global Corporations 0 s&s ® @ Steve Girgenti, Executive Chairman Peter Knight, Director John Oppenheimer, MD, Director Jamie Platt, PhD , Director Founded leading global healthcare Founding Partner of Generation Clinical Professor
Slide 17: Perspective
Perspective “Exact Sciences was founded in 1995, although it took about 15 years to get the fecal DNA test off the ground. ..The company eventually went public with an initial offering on the NASDAQ in 2001. In the early years, there was much speculation that the company would be acquired by a compe
Slide 18: May not be reproduced or distributed without permission.
May not be reproduced or distributed without permission.
bioAffinity Technologies — H.C. Wainwright Annual Global Investment Conference 2025 on 6ix